logo-loader
viewValiRx PLC

ValiRx COO Morris highlights ‘very important year’ for company

George Morris, the chief operating officer of ValiRx (LON:VAL), says 2015 is likely to be a very important year for the AIM-listed drug developer.

ValiRx today confirmed preliminary information from phase I/II trials of VAL201, its lead compound, will be available in the first quarter of this year.

Quick facts: ValiRx PLC

Price: 0.1314 GBX

AIM:VAL
Market: AIM
Market Cap: £1.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

RNS

Holding(s) in Company

17 hours, 12 minutes ago

Placing & Issue of Equity

4 weeks, 1 day ago

Half-year Report

on 26/9/19

Company Update

on 24/9/19

VAL201 Update

on 10/9/19

2 min read